Dr. Brentjens on Challenges of CAR-Modified T Cells

Video

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Getting CAR-modified T cells into the clinic was the first challenge, Brentjens says, but that is less of an obstacle now.

Now, physicians and researchers must cope with the side effects of CAR-modified T cells as well as how to address diseases where they do not work. A third challenges exists in expanding this therapy to other types of cancers. Brentjens believes investigators will focus on identifying target proteins or carbohydrates on the tumor cell surface for different tumor types. This will allow for the exploration of CAR-modified T cells in solid tumors and other types of hematologic malignancies.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.